drugset / Trial / NCT02043678

Radium-223 Dichloride and Abiraterone Acetate Compared to Placebo and Abiraterone Acetate for Men With Cancer of the Prostate When Medical or Surgical Castration Does Not Work and When the Cancer Has Spread to the Bone, Has Not Been Treated With Chemotherapy and is Causing no or Only Mild Symptoms

NCT02043678

Phase 3 Completed 806 enrolled Bayer Janssen Research & Development, LLC · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

To determine if the addition of radium-223 dichloride to standard treatment is able to prolong life and to delay events specific for prostate cancer which has spread to the bone, such as painful fractures or bone pain which needs to be treated with an X-ray machine.

Timeline

Start
2014-03-30
Primary completion
2018-02-15
Completion
2024-02-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Radium-223 dichloride Other / unclassified 50 unknown Intravenous
Subject Radium-223 dichloride Other / unclassified 55 unknown Intravenous
Background Abiraterone acetate Small molecule 1000 mg Oral
Background Prednisolone Other / unclassified 5 mg Oral
Background Prednisone Other / unclassified 5 mg Oral

Indications